NCT07513376
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07513376
Title A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) (INTerpath-014)
Acronym INTerpath-014
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN | AUS

Facility Status City State Zip Country Details
NHO Revive Research Institute, LLC ( Site 3218) RECRUITING Lincoln Nebraska 68506 United States Details
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207) RECRUITING Reno Nevada 89502 United States Details
Altru Health System ( Site 3254) RECRUITING Grand Forks North Dakota 58201 United States Details
One Clinical Research ( Site 0501) RECRUITING Nedlands Western Australia 6009 Australia Details
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503) RECRUITING Kingston Ontario K7L 2V7 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field